Is Amgen Inc. a good investment? Amgen Inc. (AMGN.MX) is currently trading at 7567.00 MXN.
In terms of valuation, the stock trades at a P/E ratio of 27.70. This valuation is generally in line with the broader market.
For income investors, Amgen Inc. pays a dividend yield of 2.25%. With a payout ratio of 61%, the dividend appears sustainable.
Yes, it pays an annual dividend of 170.38 MXN (2.25% yield).
Amgen Inc. is classified as a Stock. You can compare it against 15 other assets in the "Related Symbols" list on this page.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| Year | Total Dividends |
|---|---|
| ▸2027 |
139.65 MXN
|
| Aug. 20, 2027 (estimated) | 46.5500 |
| May 21, 2027 (estimated) | 46.5500 |
| Feb. 19, 2027 (estimated) | 46.5500 |
| ▸2026 |
172.18 MXN
|
| Nov. 20, 2026 (estimated) | 43.9638 |
| Aug. 21, 2026 | 42.7402 |
| May 15, 2026 | 42.7402 |
| Feb. 13, 2026 | 42.7402 |
| ▸2025 |
161.46 MXN
|
| Nov. 21, 2025 | 40.3658 |
| Aug. 22, 2025 | 40.3658 |
| May 16, 2025 | 40.3658 |
| Feb. 14, 2025 | 40.3658 |
| ▸2024 |
152.64 MXN
|
| Nov. 19, 2024 | 38.1609 |
| Aug. 16, 2024 | 38.1609 |
| May 16, 2024 | 38.1609 |
| Feb. 15, 2024 | 38.1609 |
| ▸2023 |
144.50 MXN
|
| Nov. 16, 2023 | 36.1257 |
| Aug. 17, 2023 | 36.1257 |
| May 17, 2023 | 36.1257 |
| Feb. 14, 2023 | 36.1257 |
| ▸2022 |
131.61 MXN
|
| Nov. 16, 2022 | 32.9032 |
| Aug. 17, 2022 | 32.9032 |
| May 16, 2022 | 32.9032 |
| Feb. 14, 2022 | 32.9032 |
| ▸2021 |
119.40 MXN
|
| Nov. 16, 2021 | 29.8503 |
| Aug. 16, 2021 | 29.8503 |
| May 14, 2021 | 29.8503 |
| Feb. 11, 2021 | 29.8503 |
| ▸2020 |
108.55 MXN
|
| Nov. 13, 2020 | 27.1366 |
| Aug. 14, 2020 | 27.1366 |
| May 15, 2020 | 27.1366 |
| Feb. 13, 2020 | 27.1366 |
| ▸2019 |
98.37 MXN
|
| Nov. 14, 2019 | 24.5926 |
| Aug. 14, 2019 | 24.5926 |
| May 16, 2019 | 24.5926 |
| Feb. 14, 2019 | 24.5926 |
| ▸2018 |
89.55 MXN
|
| Nov. 15, 2018 | 22.3877 |
| Aug. 16, 2018 | 22.3877 |
| May 16, 2018 | 22.3877 |
| Feb. 14, 2018 | 22.3877 |
| ▸2017 |
78.02 MXN
|
| Nov. 16, 2017 | 19.5045 |
| Aug. 15, 2017 | 19.5045 |
| May 15, 2017 | 19.5045 |
| Feb. 13, 2017 | 19.5045 |
| ▸2016 |
67.84 MXN
|
| Nov. 14, 2016 | 16.9604 |
| Aug. 15, 2016 | 16.9604 |
| May 13, 2016 | 16.9604 |
| Feb. 11, 2016 | 16.9604 |
| ▸2015 |
53.59 MXN
|
| Nov. 12, 2015 | 13.3987 |
| Aug. 13, 2015 | 13.3987 |
| May 12, 2015 | 13.3987 |
| Feb. 10, 2015 | 13.3987 |
| ▸2014 |
41.38 MXN
|
| Nov. 10, 2014 | 10.3458 |
| Aug. 12, 2014 | 10.3458 |
| May 13, 2014 | 10.3458 |
| Feb. 11, 2014 | 10.3458 |
| ▸2013 |
31.89 MXN
|
| Nov. 12, 2013 | 7.9714 |
| Aug. 14, 2013 | 7.9714 |
| May 14, 2013 | 7.9714 |
| Feb. 11, 2013 | 7.9714 |
| ▸2012 |
24.42 MXN
|
| Nov. 13, 2012 | 6.1057 |
| Aug. 14, 2012 | 6.1057 |
| May 14, 2012 | 6.1057 |
| Feb. 13, 2012 | 6.1057 |
| ▸2011 |
9.50 MXN
|
| Nov. 15, 2011 | 4.7489 |
| Aug. 16, 2011 | 4.7489 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Amgen Inc. | Aug 21, 2026 | Paid | 42.740208 MXN |
| Amgen Inc. | May 15, 2026 | Paid | 42.740208 MXN |
| Amgen Inc. | Feb 13, 2026 | Paid | 42.740208 MXN |
| Amgen Inc. | Nov 21, 2025 | Paid | 40.365753 MXN |
Community Discussion